These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 28146421)

  • 1. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
    Booth L; Roberts JL; Sander C; Lee J; Kirkwood JM; Poklepovic A; Dent P
    Oncotarget; 2017 Mar; 8(10):16367-16386. PubMed ID: 28146421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling.
    Dent P; Booth L; Poklepovic A; Kirkwood JM
    Pigment Cell Melanoma Res; 2022 Jan; 35(1):66-77. PubMed ID: 34482636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide.
    Booth L; Roberts JL; Poklepovic A; Gordon S; Dent P
    Oncotarget; 2017 Jan; 8(1):1449-1468. PubMed ID: 27903966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα
    Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P
    Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo.
    Booth L; Albers T; Roberts JL; Tavallai M; Poklepovic A; Lebedyeva IO; Dent P
    Oncotarget; 2016 Jun; 7(26):40398-40417. PubMed ID: 27259258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
    Booth L; Roberts JL; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
    Cancer Biol Ther; 2018 Mar; 19(3):239-247. PubMed ID: 29333953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.
    Liu L; Mayes PA; Eastman S; Shi H; Yadavilli S; Zhang T; Yang J; Seestaller-Wehr L; Zhang SY; Hopson C; Tsvetkov L; Jing J; Zhang S; Smothers J; Hoos A
    Clin Cancer Res; 2015 Apr; 21(7):1639-51. PubMed ID: 25589619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib.
    Booth L; Roberts JL; Poklepovic A; Dent P
    Front Oncol; 2019; 9():650. PubMed ID: 31380285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pazopanib and HDAC inhibitors interact to kill sarcoma cells.
    Tavallai S; Hamed HA; Grant S; Poklepovic A; Dent P
    Cancer Biol Ther; 2014 May; 15(5):578-85. PubMed ID: 24556916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells.
    Booth L; West C; Von Hoff D; Kirkwood JM; Dent P
    Front Oncol; 2021; 11():656453. PubMed ID: 33898322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GZ17-6.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacy.
    Booth L; Roberts JL; West C; Von Hoff D; Dent P
    J Cell Physiol; 2020 Nov; 235(11):8098-8113. PubMed ID: 31951027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.
    Booth L; Roberts JL; Tavallai M; Webb T; Leon D; Chen J; McGuire WP; Poklepovic A; Dent P
    Oncotarget; 2016 Apr; 7(15):19620-30. PubMed ID: 26934000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of ERK1/2 Causes Pazopanib Resistance via Downregulation of DUSP6 in Synovial Sarcoma Cells.
    Yokoyama N; Matsunobu T; Matsumoto Y; Fukushi JI; Endo M; Hatano M; Nabeshima A; Fukushima S; Okada S; Iwamoto Y
    Sci Rep; 2017 Mar; 7():45332. PubMed ID: 28350009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
    Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
    Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valproate augments Niraparib killing of tumor cells.
    Booth L; Roberts JL; Rais R; Poklepovic A; Dent P
    Cancer Biol Ther; 2018; 19(9):797-808. PubMed ID: 29923797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cells.
    Roberts JL; Poklepovic A; Booth L; Dent P
    Cell Signal; 2020 Jun; 70():109573. PubMed ID: 32087304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (Curcumin+sildenafil) enhances the efficacy of 5FU and anti-PD1 therapies in vivo.
    Dent P; Booth L; Roberts JL; Poklepovic A; Hancock JF
    J Cell Physiol; 2020 Oct; 235(10):6862-6874. PubMed ID: 31985048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GZ17-6.02 and axitinib interact to kill renal carcinoma cells.
    Booth L; West C; Moore RP; Hoff DV; Dent P
    Oncotarget; 2022; 13():281-290. PubMed ID: 35136485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vemurafenib/dabrafenib and trametinib.
    Rissmann R; Hessel MH; Cohen AF
    Br J Clin Pharmacol; 2015 Oct; 80(4):765-7. PubMed ID: 25847075
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.
    Caporali S; Alvino E; Lacal PM; Levati L; Giurato G; Memoli D; Caprini E; Antonini Cappellini GC; D'Atri S
    Int J Oncol; 2016 Sep; 49(3):1164-74. PubMed ID: 27572607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.